-
YAP Produits associés (75)
Produits associés (75)
-
BAY-593 hydrochloride
0 ImagesCat. No.: HY-161573BCAS No.: 2413020-57-0BAY-593 (hydrochloride) is an orally active GGTase-I inhibitor. BAY-593 (hydrochloride) can block YAP1/TAZ signaling in animals and has antitumor activity.
-
EN171
0 ImagesEN171 is a covalent 14-3-3σ molecular glue ligand that sequesters neonuclear substrates, including BRD4 and BLC6, into the cytoplasm by recruiting 14-3-3σ. EN171 covalently targets C38 and C96 on 14-3-3 to enhance the interaction between 14-3-3 and ERα, YAP, and TAZ (with EC50 values of 9 μM for human ERα, 45 μM for YAP, and 107 μM for TAZ). EN171 inhibits the transcriptional activity of estrogen receptors and the Hippo pathway in breast cancer cells. EN171 can be used in studies related to breast cancer.
-
6-Methoxydihydrosanguinarine hydrochloride
0 ImagesCat. No.: HY-N3000A6-Methoxydihydrosanguinarine hydrochloride is an alkaloid with activity across multiple cancer cell types. 6-Methoxydihydrosanguinarine hydrochloride activates IRE1/JNK signaling, blocks Akt/mTOR and PI3K/AKT/mTOR pathways, reduces expression of Cdc25C, CyclinB1, Cdc2, YAP/TAZ, Survivin, GPX4, and EGFR, upregulates IRE1 and DR5, and activates JNK and caspases. 6-Methoxydihydrosanguinarine hydrochloride induces apoptosis, G2/M phase arrest, DNA damage, ROS generation, lipid peroxidation, ferroptosis, autophagy, and suppresses cancer cell growth. 6-Methoxydihydrosanguinarine hydrochloride disruptes the biofilm formation of Candida albicans (C. albicans). 6-Methoxydihydrosanguinarine hydrochloride can be used for the research of non-small cell lung cancer, hepatocellular carcinoma, melanoma, colon carcinoma, ovarian cancer and breast cancer.
-
Ki16425 (Standard)
0 ImagesSynonyms: Debio 0719 (Standard)Ki16425 (Standard) is the analytical standard of Ki16425. This product is intended for research and analytical applications. Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK. Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells.
-
IAG933 (Standard)
0 ImagesCat. No.: HY-153811RCAS No.: 2714434-21-4Synonyms: YAP-TEAD-IN-3 (Standard)IAG933 (Standard) is the analytical standard of IAG933 (HY-153811). This product is intended for research and analytical applications. IAG933 (YAP-TEAD-IN-3) is an orally available YAP/TAZ-TEAD inhibitor that has anti-tumor effects and promotes apoptosis. IAG933 YAP-TEAD-IN-3 inhibits Avi-human TEAD4217-434, with an IC50 value of 9 nM.
-
YAP/TAZ inhibitor-1 (Standard)
0 ImagesCat. No.: HY-111429RCAS No.: 2093565-23-0YAP/TAZ inhibitor-1 (Standard) is the analytical standard of YAP/TAZ inhibitor-1 (HY-111429). This product is intended for research and analytical applications. YAP/TAZ inhibitor-1 is a YAP/TAZ inhibitor extracted from patent WO2017058716A1, Compound 1, has an IC50 of <0.100 μΜ in firefly luciferase assay.
-
VT3989 (Standard)
0 ImagesCat. No.: HY-400902RCAS No.: 2506273-81-8VT3989 (Standard) is the analytical standard of VT3989 (HY-400902). This product is intended for research and analytical applications. VT3989 is an orally active pan-TEAD autopalmitoylation inhibitor that modulates the Hippo signaling pathway. VT3989 directly binds to TEAD transcription factors to block their palmitoylation modification, thereby disrupting the formation of YAP/TAZ-TEAD complexes and inhibiting downstream oncogenic transcriptional activity. VT3989 effectively inhibits the growth of NF2-deficient schwannoma and meningioma cells and reverses the Schwann cell phenotype. In addition, VT3989 exerts a synergistic effect when combined with Osimtinib (HY-15772) in EGFR-mutant non-small cell lung cancer models, significantly delaying tumor recurrence and prolonging survival. VT3989 can be used for the research of epithelioid hemangioendothelioma, malignant pleural mesothelioma, type 2 neurofibromatosis and related advanced solid tumors.
-
DC-TEADin04
0 ImagesCat. No.: HY-160657CAS No.: 2380228-38-4DC-TEADin04 has weak inhibitory activity against TEAD4 palmitoylation.
-
TDI-011536 (Standard)
0 ImagesCat. No.: HY-150042RCAS No.: 2687970-96-1TDI-011536 (Standard) is the analytical standard of TDI-011536 (HY-150042). This product is intended for research and analytical applications. TDI-011536 is a potent Lats Kinase inhibitor, interrupts Hippo-Yap signaling and initiates the proliferation of lesioned heartmuscle cells. TDI-011536 can be used in studies of organ conservation and regeneration.
-
PY-60 (Standard)
0 ImagesCat. No.: HY-141644RCAS No.: 2765218-56-0PY-60 (Standard) is the analytical standard of PY-60 (HY-141644). This product is intended for research and analytical applications. PY-60 is a robust and specific activator of YAP transcriptional activity that targets annexin A2 (ANXA2) with a Kd of 1.4 µM. PY-60 directly binds to ANXA2 and antagonizes its normal cellular function of repressing YAP activity.
-
Cytochalasin D (Standard)
0 ImagesCat. No.: HY-N6682RCAS No.: 22144-77-0Synonyms: Zygosporin A (Standard); NSC 209835 (Standard)Cytochalasin D (Standard) is the analytical standard of Cytochalasin D (HY-N6682). This product is intended for research and analytical applications. Cytochalasin D (Zygosporin A) is a potent actin polymerization inhibitor, could be derived from fungus. Cytochalasin D has cell-permeable activity. Cytochalasin D inhibits the G-actin–cofilin interaction by binding to G-actin. Cytochalasin D also inhibits the binding of cofilin to F-actin and decreases the rate of both actin polymerization and depolymerization in living cells. Cytochalasin D can reduce exosome release, in turn reducing the amount of survivin present in the tumour environment. Cytochalasin D induces phosphorylation and cytoplasmic retention of Yap.
